The success of life sciences companies will depend on products and services not yet found in a companies offerings in the next decade. Much of those products will be brought to companies through the merger and acquisitions of small to mid-sized companies. This panel discussed:
- When is the right time to get acquired?
- What is the survival rate of c-suite after an acquisition?
- Why is an acquisition better than a collaboration?
- What are the key issues in the due diligence process that can hurt the value of the deal?
- How does big pharma prepare for pricing negotiations and how can a smaller seller be prepared
- What types of steps can be taken to prepare a forecast that drives value negotiations
- How can this analysis be leverage in negotiating a collaborative or co-partner agreement
Presenters included:
- Todd Boudreau, Senior Counsel, Private Equity & Venture Capital Practice, Foley
- Dr. Ton Bunt, Senior Advisor, JSB Partners LP
- Sven Riethmueller, Of Counsel, Private Equity & Venture Capital, Foley
- David Schechner, Managing Director, Canaccord Adams
- Shane Senior, Managing Director, Crosstree Capital Partners Inc.
Related Insights
10 January 2025
Foley Ignite
The Outlook for US Private Equity in 2025
As we launch into the next quarter century, there is much speculation about what the future holds for private equity (PE) as an asset class and driver in dealmaking.
10 January 2025
Foley Viewpoints
Tax Court Reaffirms Soroban Holding that “Active” Limited Partners are Subject to Self-Employment Tax
On December 23, 2024, the Tax Court ruled in Denham Capital Management LP v. Commissioner (T.C. Memo. 2024-114), that limited partners that actively participated in the activities of a fund manager formed as a state law limited partnership were subject to self-employment tax on all of their distributive share of income from the partnership.
09 January 2025
Foley Viewpoints